{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:49:03Z","timestamp":1791542943146,"version":"4.3.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.japh.2026.103522","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:15:44Z","timestamp":1789427744000},"page":"103522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expanding access to medications for opioid use disorder through pharmacist scope-of-practice flexibility"],"prefix":"10.1016","volume":"66","author":[{"given":"Alex J.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.japh.2026.103522_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamapsychiatry.2024.0810","article-title":"Estimated number of children who lost a parent to drug overdose in the U.S. from 2011 to 2021","volume":"81","author":"Jones","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2026.103522_bib2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2026.103522_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2208055","article-title":"Physician-delegated unobserved induction with buprenorphine in pharmacies","volume":"388","author":"Green","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.japh.2026.103522_bib4","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2026.103522_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2026.103048","article-title":"Expanding access to MOUD through pharmacist independent prescribing: early findings from a community pharmacy-based clinical service","volume":"66","author":"O'Connor","year":"2026","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2026.103522_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.japh.2023.04.016","article-title":"The impact of the Mainstreaming Addiction Treatment Act and associated legislative action on pharmacy practice","volume":"63","author":"Varisco","year":"2023","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2026.103522_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.japh.2023.04.029","article-title":"Addressing buprenorphine bottlenecks in the context of MAT Act implementation: a shared responsibility","volume":"63","author":"Ostrach","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.japh.2026.103522_bib8","series-title":"SUPPORT for Patients and Communities Reauthorization Act of 2025, Pub L No. 119-44, 139 Stat 669, Washington, DC","year":"2025"},{"issue":"6","key":"10.1016\/j.japh.2026.103522_bib9","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.japh.2020.07.013","article-title":"Rethinking pharmacy regulation: core elements of Idaho's transition to a \u201cStandard of Care\u201d approach","volume":"60","author":"Adams","year":"2020","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"10.1016\/j.japh.2026.103522_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.02.007","article-title":"How to implement a \u201cstandard of care\u201d regulatory model for pharmacists","volume":"64","author":"Adams","year":"2024","journal-title":"J Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2026.103522_bib11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.japh.2023.06.001","article-title":"Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act","volume":"63","author":"Athay Adams","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.japh.2026.103522_bib12","author":"Adams"},{"issue":"8","key":"10.1016\/j.japh.2026.103522_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27236","article-title":"Pharmacy naloxone standing order and community opioid fatality rates over time","volume":"7","author":"Xuan","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126005078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126005078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:50:52Z","timestamp":1791539452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126005078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1544319126005078"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103522","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding access to medications for opioid use disorder through pharmacist scope-of-practice flexibility","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"103522"}}